[HTML][HTML] Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma
AGM Mostofa, A Distler, MB Meads, E Sahakian… - JCI insight, 2021 - ncbi.nlm.nih.gov
The clinical utility of histone/protein deacetylase (HDAC) inhibitors in combinatorial
regimens with proteasome inhibitors for patients with relapsed and refractory multiple …
regimens with proteasome inhibitors for patients with relapsed and refractory multiple …
Dual-targeted therapy circumvents non-genetic drug resistance to targeted therapy
W Wang, Y Sun, X Liu, SK Kumar, F Jin, Y Dai - Frontiers in Oncology, 2022 - frontiersin.org
The introduction of various targeted agents into the armamentarium of cancer treatment has
revolutionized the standard care of patients with cancer. However, like conventional …
revolutionized the standard care of patients with cancer. However, like conventional …